Research Article
Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients
Table 3
Patients’ characteristics of young versus old patients.
| | | Patients 18–49 years n (%) | Patients >49 years n (%) |
| | Total number | 767 (70.3) | 324 (29.7) | | CD | 412 (53.7) | 171 (52.8) | | UC | 355 (46.3) | 153 (47.2) | | Female | 420 (54.8) | 178 (54.9) | | No immunotherapy | 172 (22.4) | 77 (23.8) | | With immunotherapy | 595 (77.6) | 247 (76.2) | | TNF-alpha blockers: infliximab, adalimumab, golimumab | 347 (45.2) | 128 (27.0) | | Infliximab | 272 (35.5) | 98 (26.5) | | Adalimumab | 70 (9.1) | 25 (26.3) | | Ustekinumab | 104 (13.6) | 50 (32.5) | | Vedolizumab | 107 (14.9) | 39 (26.7) | | Immunotherapy combinations | 42 (5.5) | 3 (6.7) |
|
|
